Satellos Bioscience Inc. (TSX:MSCL)
Canada · Delayed Price · Currency is CAD 13.38
-0.47 (-3.39%)
Aug 14, 2026, 3:59 PM EST
Satellos Bioscience Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Operating Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -28.5 | -24.87 | -20.63 | -12.03 | -8.37 | -12.25 |
Depreciation & Amortization | 0 | 0 | 0.02 | 0.01 | 0.25 | 0.13 |
Asset Writedown & Restructuring Costs | - | - | 2.91 | - | 2.13 | - |
Loss (Gain) From Sale of Investments | - | - | - | - | -0.03 | - |
Stock-Based Compensation | 3.32 | 3.24 | 1.64 | 1.64 | 1.06 | 0.77 |
Other Operating Activities | -0.32 | -0.48 | -1.43 | 1.33 | 0.05 | 7.76 |
Change in Accounts Receivable | - | - | - | - | - | 0.03 |
Change in Accounts Payable | 1.81 | 0.5 | 1.01 | 0.6 | 0.54 | -0.31 |
Change in Other Net Operating Assets | -2.13 | -1.98 | -1.77 | -0.32 | 0.2 | -0.11 |
Operating Cash Flow | -25.82 | -23.6 | -18.25 | -8.77 | -4.17 | -3.98 |
Operating Cash Flow Growth | - | - | - | - | - | - |
Investing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Capital Expenditures | -0.01 | -0.01 | -0 | -0.01 | -0 | -0.01 |
Cash Acquisitions | - | - | - | - | - | 1.38 |
Investment in Securities | -42.74 | -9.41 | 4.66 | -13.27 | - | - |
Investing Cash Flow | -42.75 | -9.42 | 4.66 | -13.28 | -0 | 1.37 |
Financing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Short-Term Debt Issued | - | - | - | 1.81 | - | - |
Long-Term Debt Issued | - | - | - | - | - | 0.15 |
Total Debt Issued | - | - | - | 1.81 | - | 0.15 |
Short-Term Debt Repaid | - | - | - | -1.99 | - | - |
Total Debt Repaid | - | - | - | -1.99 | - | - |
Net Debt Issued (Repaid) | - | - | - | -0.18 | - | 0.15 |
Issuance of Common Stock | 49.49 | 2.24 | 30.66 | 26.62 | 1.47 | 5.74 |
Other Financing Activities | 4.65 | - | 6.92 | 11.74 | 0.58 | - |
Financing Cash Flow | 54.14 | 2.24 | 37.57 | 38.19 | 2.05 | 5.89 |
Net Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Foreign Exchange Rate Adjustments | 0.41 | 0.5 | -0.59 | -0.88 | -0.06 | -0 |
Net Cash Flow | -14.02 | -30.27 | 23.39 | 15.25 | -2.18 | 3.28 |
Free Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -25.83 | -23.6 | -18.26 | -8.79 | -4.17 | -3.98 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Per Share | -1.64 | -1.62 | -1.91 | -1.22 | -1.40 | -1.99 |
Levered Free Cash Flow | -15.72 | -14.76 | -11.72 | -5.49 | -1.85 | -0.13 |
Unlevered Free Cash Flow | -15.72 | -14.76 | -11.72 | -5.41 | -1.85 | -0.1 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Change in Working Capital | -0.32 | -1.48 | -0.75 | 0.28 | 0.73 | -0.38 |